In June, BioCentriq hosted a webinar called End-to-End Automated Manufacturing of Low-Seed CAR-T Cells where we explored the intricate pathway to achieving commercial readiness in CAR-T cell therapy. In this session, we address crucial aspects such as scalability, process development, cost management, and GMP compliance.
CAR-T cell therapy represents a significant advancement in regenerative medicine, but the journey to commercialization is complex. This comprehensive study conducted in partnership with Terumo Blood and Cell Technologies, highlighted key factors necessary for a successful manufacturing process.
Read on to see who participated and what we discussed!
Speaker: David Smith, Ph.D.
Vice President, Development, BioCentriq
David Smith is the Vice President at BioCentriq, leading the Manufacturing, Science, and Technology (MS&T), Process Development, and Analytical Method Development teams. With over 15 years in regenerative medicine, he has significant experience in advancing cell therapy manufacturing. David has previously held key roles at Ori Biotech and Minaris Regenerative Medicine, focusing on process optimization and quality assurance. His expertise includes experimental design and quality-by-design, contributing to advancements in CAR-T cell production. David is committed to driving innovation and ensuring compliance with industry standards for efficient, scalable manufacturing.
Key Highlights:
- Cell Expansion Dynamics: Comprehensive data on CAR-T cell expansion kinetics and deep phenotypic characterization.
- Technology Transfer Insights: Learn about the rapid and effective transfer of an end-to-end manufacturing protocol to a contracted site, ensuring seamless integration and operation.
- Functional Assays Results: Gain insights into the outcomes of cell killing assays and cytokine re-stimulation responses, crucial for evaluating therapy effectiveness.
What We Covered:
- Strategies to scale CAR-T cell production while maintaining high-quality standards.
- Effective methods for optimizing processes and managing costs.
- Detailed findings from our collaboration with Terumo Blood and Cell Technologies, focusing on the Quantum Flex Cell Expansion System.
How You Can Watch The Webinar On-Demand? Simply click on “Watch Now” at the top of this page
Learn more about this partnership here!